Phenotypes Associated with This Genotype

Genotype
MGI:5448537

• Allelic Composition: Mir122^tm1.2Kgh/Mir122^tm1.2Kgh; Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Abnormal liver structure in Mir122^tm1.2Kgh/Mir122^tm1.2Kgh Speer6-ps1^{Tg(Alb-cre)21Mgn}/0 mice

endocrine/exocrine glands

bile duct proliferation ( J:190067 )

• increased

homeostasis/metabolism

increased circulating interleukin-6 level ( J:190067 )

♂ • in tumor-bearing male mice

abnormal circulating enzyme level ( J:190067 )

• increase in serum gamma-glutamyl transpeptidase

increased circulating alanine transaminase level ( J:190067 )

• in tumor-bearing mice

increased circulating alkaline phosphatase level ( J:190067 )

• 2-fold as early as 5 weeks of age

• in tumor-bearing mice

decreased liver glycogen level ( J:190067 )

• 2.5-fold at 8 to 10 weeks of age

• at 6 months of age

abnormal lipid homeostasis ( J:190067 )

• mice exhibit a small increase in de novo triglyceride synthesis compared with control mice

decreased circulating cholesterol level ( J:190067 )

• as early as 5 weeks of age

decreased circulating HDL cholesterol level ( J:190067 )

• as early as 5 weeks of age

decreased circulating LDL cholesterol level ( J:190067 )

• as early as 5 weeks of age

increased bile salt level ( J:190067 )

• in tumor-bearing mice

increased liver triglyceride level ( J:190067 )

• 2.5-fold at 8 to 10 weeks of age

• at 6 months of age

liver/biliary system

bile duct proliferation ( J:190067 )

• increased

decreased liver glycogen level ( J:190067 )

• 2.5-fold at 8 to 10 weeks of age

• at 6 months of age

increased liver triglyceride level ( J:190067 )

• 2.5-fold at 8 to 10 weeks of age

• at 6 months of age

microvesicular hepatic steatosis ( J:190067 )

liver fibrosis ( J:190067 )

increased liver tumor incidence ( J:190067 )

♂ • at 12 to 17 months, 13 of 26 male mice develop liver tumors

increased hepatocellular carcinoma incidence ( J:190067 )

♀ • in 2 of 20 mice at 12 to 17 months of age

abnormal liver physiology ( J:190067 )

• mice exhibit a small increase in de novo triglyceride synthesis and reduced triglyceride secretion in the liver compared with control mice

liver inflammation ( J:190067 )

• steatohepatitis with bridging fibrosis

• recruitment of monocytes and neutrophils to the liver

abnormal oval cell physiology ( J:190067 )

• increased proliferation

neoplasm

increased liver tumor incidence ( J:190067 )

♂ • at 12 to 17 months, 13 of 26 male mice develop liver tumors

increased hepatocellular carcinoma incidence ( J:190067 )

♀ • in 2 of 20 mice at 12 to 17 months of age

immune system

increased neutrophil cell number ( J:190067 )

• 3-fold in the liver at 10 months

increased monocyte cell number ( J:190067 )

• 3-fold in the liver at 10 months

increased circulating interleukin-6 level ( J:190067 )

♂ • in tumor-bearing male mice

increased interleukin-6 secretion ( J:190067 )

♂ • from monocytes and neutrophils in the liver

increased tumor necrosis factor secretion ( J:190067 )

• from monocytes and neutrophils in the liver

liver inflammation ( J:190067 )

• steatohepatitis with bridging fibrosis

• recruitment of monocytes and neutrophils to the liver

hematopoietic system

increased neutrophil cell number ( J:190067 )

• 3-fold in the liver at 10 months

increased monocyte cell number ( J:190067 )

• 3-fold in the liver at 10 months